期刊文献+

酪氨酸蛋白激酶抑制兔角膜新生血管的实验研究

Inhibition of corneal neovascularization by tyrosine protein kinase inhibitor
下载PDF
导出
摘要 目的:探讨酪氨酸蛋白激酶抑制剂sunitinib对碱烧伤诱导的兔角膜新生血管的抑制作用。方法:采用碱烧伤法诱导兔角膜新生血管模型。将30只新西南大白兔随机分为3组,A组:给予0.5mg/ml sunitinib滴眼,B组:给予1mg/ml sunitinib滴眼,C组:给予生理盐水滴眼作为实验对照组。于碱烧伤后4d、7d、14d显微镜观测新生血管长度及面积。在4d、14d时各组处死4只兔,角膜作病理分析和免疫组织化学法测定血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达。结果A、B组的角膜新生血管长度及面积均显著少于C组(p<0.01);A、B组VEGF蛋白表达较C组弱,具有统计学差异(p<0.01);结论:酪氨酸蛋白酶抑制剂sunitinib能降低兔角膜碱烧伤后角膜VEGF的表达,有效抑制角膜新生血管的形成。 Objective:To study the inhibit effects of tyrosine protein kinase inhibitor sunitinib on corneal neovascularization.Methods:The corneal neovascularization was induced by corneal alkali burn.The rats were randomly divided into 3 groups.0.5,lmg/ml sunitinib eye drops was topically administrated in Group A and Group B.Group C was treated with sodium cholride as blank control.The lenth and area of CNV in each group were examined by microscope at days4,7and 14 day following the injury.Corneas were excised at day 4 and 14 for histopathological examinations.Results The corneal neovascularization area in groups A and B were smaller than group C in 4,7,14days.(p〈0.01).the expression of VEGF in cornea was obviously reduced in group A and group B compared with group C in 4 and 7 days.(p〈0.01).Conclusion tyrosine protein kinase inhibitor sunitinib can inhibit the growth of corneal neovascularization induced by alkaline burning in rats effetively,and reduce the expression of VEGF in cornea.
出处 《激光杂志》 CAS CSCD 北大核心 2010年第3期80-81,共2页 Laser Journal
关键词 酪酸蛋激酶抑制剂 角膜新生血管 角膜碱烧伤 tyrosine protein kinase inhibitor corneal neovascularization corneal alkali burn
  • 相关文献

参考文献10

  • 1Motzeb IU, Hoosen S, Bello CL, et al. Sunitinib malate for the treatment of solid tumours: a review of current clinical data[J]. Expert Opin Investig Drugs,2006,15(5) :553 - 561.
  • 2Imarrishl J, Kamiymm K, Iguchi I et al. Growth factors: importance in wound healingand maintenance of transparency of the cornea[J].Prog Reina eye Res,2000,19(1): 113- 129.
  • 3Hamrah P, Dana MR. Corneal antigen-presenting cells[J].Chemimmunol Allergy,2007, 92: 58-70.
  • 4Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor - type tyrosine kinase gene(f10 closely related to the fins family. Oncogene, 1990, 5(4): 519- 524.
  • 5Goodman VL, Rock EP, Dagherr, et al. Approval summary:sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma [J]. Clin Cancer Res, 2007, 13(5): 1367- 1373.
  • 6Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor- induced responses and turner growth after oral administration. Cancer Res, 2000,60:2178 - 2189.
  • 7Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res, 2000,60:4819 - 4824.
  • 8Pock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci,2007,48:2545- 2552.
  • 9Joseph A. Blansfield, 1 Diana Caragacianu, et al. Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy. Cancer Therapy: Preclinical, 2008, 14 ( 1 ) : 270 --280.
  • 10Oukas J, Mahesh S, Umeda N,et al.Topical administration of a multi - targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol,2008,216(1) :29- 37.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部